Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Incyte Corporation
Incyte Corporation
Agenus Inc.
Genexine, Inc.
Stanford University
National Institutes of Health Clinical Center (CC)
Baylor College of Medicine
Cancer Research and Biostatistics Clinical Trials Consortium
Dana-Farber Cancer Institute
Merck Sharp & Dohme LLC
Revolution Medicines, Inc.
Advaxis, Inc.
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Gilead Sciences
Seagen Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Institutes of Health Clinical Center (CC)
University of Southern California
Radiation Therapy Oncology Group